Karyopharm Therapeutics's quarterly market cap
increased
from Sep. 2025 ($56.9 Mil) to Dec. 2025 ($134.8 Mil) but then
declined
from Dec. 2025 ($134.8 Mil) to Mar. 2026 ($125.6 Mil).
Karyopharm Therapeutics's annual market cap
declined
from Dec. 2023 ($99.4 Mil) to Dec. 2024 ($85.3 Mil) but then
increased
from Dec. 2024 ($85.3 Mil) to Dec. 2025 ($134.8 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Karyopharm Therapeutics's Enterprise Value for Today is $361.1 Mil.
Karyopharm Therapeutics (NAS:KPTI) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Karyopharm Therapeutics Market Cap Related Terms
Karyopharm Therapeutics Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Karyopharm Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Karyopharm Therapeutics Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Karyopharm Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Karyopharm Therapeutics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Karyopharm Therapeutics's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Karyopharm Therapeutics (KPTI) has a Market Cap of $221.1 Mil as of Jul. 01, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Karyopharm Therapeutics and its competitors. According to the industry distribution chart, Karyopharm Therapeutics ranks #577 out of 1427 companies in the Biotechnology industry, placing it in the top 40.4%.
Is Karyopharm Therapeutics' Market Cap too high?
Karyopharm Therapeutics' current Market Cap is $221.1 Mil. The Biotechnology industry median Market Cap is 119.57. Karyopharm Therapeutics' value of $221.1 Mil is 84.9% above this industry median. Based on the distribution chart, Karyopharm Therapeutics ranks #577 out of 1427 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Karyopharm Therapeutics has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Karyopharm Therapeutics' Market Cap compare to CHRS and TARA?
According to the Biotechnology industry distribution chart, Karyopharm Therapeutics ranks #577 out of 1427 companies for Market Cap. This puts Karyopharm Therapeutics in the upper half of its industry. The industry median Market Cap is 119.57. Karyopharm Therapeutics' value of $221.1 Mil is 84.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 119.57, based on 1,427 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Karyopharm Therapeutics's current Market Cap of $221.1 Mil is 84.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Karyopharm Therapeutics and its competitors. For the Biotechnology industry, the median Market Cap is 119.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Karyopharm Therapeutics's current Market Cap is $221.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Karyopharm Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Karyopharm Therapeutics (KPTI) is currently considered Significantly Overvalued. The stock's GF Value™ is $6.39, compared to a current price of $9.76 — trading 52.7% above its estimated fair value. The current Market Cap is $221.1 Mil and 84.9% above the Biotechnology industry median of 119.57. Karyopharm Therapeutics' overall GF Score™ is 52/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Karyopharm Therapeutics (KPTI), the current Market Cap is $221.1 Mil as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Karyopharm Therapeutics (KPTI) Overvalued in 2026?
Based on GuruFocus' analysis, Karyopharm Therapeutics stock appears to be overvalued.
The current stock price of $9.76 is trading 52.7% above its estimated GF Value™ of $6.39.
GuruFocus considers Karyopharm Therapeutics to be Significantly Overvalued.
Key valuation signals for KPTI:
Market Cap: $221.1 Mil
GF Value™: $6.39 vs. price of $9.76 (52.7% above fair value)
Industry Position: 84.9% above the Biotechnology median (#577 of 1427)
No single metric tells the full story. See the KPTI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).
52GF Score
Get the complete analysis for KPTI
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KPTI has been successfully added to your 
